William Blair analyst Matt Phipps has reiterated their bullish stance on EVMN stock, giving a Buy rating on December 12.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Matt Phipps has given his Buy rating due to a combination of factors that highlight the potential of Evommune, Inc.’s EVO756. Despite initial concerns stemming from the minimal activity observed in the EP262 trial for chronic spontaneous urticaria, Phipps emphasizes that these results are likely due to specific liabilities of the EP262 molecule, such as poor absorption and biodistribution.
Phipps points out that EVO756 has demonstrated sufficient biodistribution to the skin and on-target activity in previous trials, which supports its potential success in the ongoing Phase II trial. The expected outcomes of this trial, anticipated in the first half of 2026, contribute to the confidence in the stock’s performance, justifying the Buy rating.
In another report released on December 12, Morgan Stanley also maintained a Buy rating on the stock with a $36.00 price target.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EVMN in relation to earlier this year.